207 related articles for article (PubMed ID: 22984513)
1. Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging.
Marcellin D; Abramowski D; Young D; Richter J; Weiss A; Marcel A; Maassen J; Kauffmann M; Bibel M; Shimshek DR; Faull RL; Bates GP; Kuhn RR; Van der Putten PH; Schmid P; Lotz GP
PLoS One; 2012; 7(9):e44457. PubMed ID: 22984513
[TBL] [Abstract][Full Text] [Related]
2. TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease.
Baldo B; Paganetti P; Grueninger S; Marcellin D; Kaltenbach LS; Lo DC; Semmelroth M; Zivanovic A; Abramowski D; Smith D; Lotz GP; Bates GP; Weiss A
Chem Biol; 2012 Feb; 19(2):264-75. PubMed ID: 22365609
[TBL] [Abstract][Full Text] [Related]
3. A novel human embryonic stem cell-derived Huntington's disease neuronal model exhibits mutant huntingtin (mHTT) aggregates and soluble mHTT-dependent neurodegeneration.
Lu B; Palacino J
FASEB J; 2013 May; 27(5):1820-9. PubMed ID: 23325320
[TBL] [Abstract][Full Text] [Related]
4. Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein.
Fox JH; Connor T; Stiles M; Kama J; Lu Z; Dorsey K; Lieberman G; Sapp E; Cherny RA; Banks M; Volitakis I; DiFiglia M; Berezovska O; Bush AI; Hersch SM
J Biol Chem; 2011 May; 286(20):18320-30. PubMed ID: 21454633
[TBL] [Abstract][Full Text] [Related]
5. Meso scale discovery-based assays for the detection of aggregated huntingtin.
Reindl W; Baldo B; Schulz J; Janack I; Lindner I; Kleinschmidt M; Sedaghat Y; Thiede C; Tillack K; Schmidt C; Cardaun I; Schwagarus T; Herrmann F; Hotze M; Osborne GF; Herrmann S; Weiss A; Zerbinatti C; Bates GP; Bard J; Munoz-Sanjuan I; Macdonald D
PLoS One; 2019; 14(3):e0213521. PubMed ID: 30913220
[TBL] [Abstract][Full Text] [Related]
6. Mutant huntingtin gene-dose impacts on aggregate deposition, DARPP32 expression and neuroinflammation in HdhQ150 mice.
Young D; Mayer F; Vidotto N; Schweizer T; Berth R; Abramowski D; Shimshek DR; van der Putten PH; Schmid P
PLoS One; 2013; 8(9):e75108. PubMed ID: 24086450
[TBL] [Abstract][Full Text] [Related]
7. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.
Gray M; Shirasaki DI; Cepeda C; André VM; Wilburn B; Lu XH; Tao J; Yamazaki I; Li SH; Sun YE; Li XJ; Levine MS; Yang XW
J Neurosci; 2008 Jun; 28(24):6182-95. PubMed ID: 18550760
[TBL] [Abstract][Full Text] [Related]
8. Formation and toxicity of soluble polyglutamine oligomers in living cells.
Lajoie P; Snapp EL
PLoS One; 2010 Dec; 5(12):e15245. PubMed ID: 21209946
[TBL] [Abstract][Full Text] [Related]
9. Comparison of mHTT Antibodies in Huntington's Disease Mouse Models Reveal Specific Binding Profiles and Steady-State Ubiquitin Levels with Disease Development.
Bayram-Weston Z; Jones L; Dunnett SB; Brooks SP
PLoS One; 2016; 11(5):e0155834. PubMed ID: 27196694
[TBL] [Abstract][Full Text] [Related]
10. Fractionation for Resolution of Soluble and Insoluble Huntingtin Species.
Ochaba J; Morozko EL; O'Rourke JG; Thompson LM
J Vis Exp; 2018 Feb; (132):. PubMed ID: 29553509
[TBL] [Abstract][Full Text] [Related]
11. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.
Moffitt H; McPhail GD; Woodman B; Hobbs C; Bates GP
PLoS One; 2009 Nov; 4(11):e8025. PubMed ID: 19956633
[TBL] [Abstract][Full Text] [Related]
12. Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease.
Weiss A; Abramowski D; Bibel M; Bodner R; Chopra V; DiFiglia M; Fox J; Kegel K; Klein C; Grueninger S; Hersch S; Housman D; Régulier E; Rosas HD; Stefani M; Zeitlin S; Bilbe G; Paganetti P
Anal Biochem; 2009 Dec; 395(1):8-15. PubMed ID: 19664996
[TBL] [Abstract][Full Text] [Related]
13. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.
Weiss A; Träger U; Wild EJ; Grueninger S; Farmer R; Landles C; Scahill RI; Lahiri N; Haider S; Macdonald D; Frost C; Bates GP; Bilbe G; Kuhn R; Andre R; Tabrizi SJ
J Clin Invest; 2012 Oct; 122(10):3731-6. PubMed ID: 22996692
[TBL] [Abstract][Full Text] [Related]
14. Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease.
Lu XH; Mattis VB; Wang N; Al-Ramahi I; van den Berg N; Fratantoni SA; Waldvogel H; Greiner E; Osmand A; Elzein K; Xiao J; Dijkstra S; de Pril R; Vinters HV; Faull R; Signer E; Kwak S; Marugan JJ; Botas J; Fischer DF; Svendsen CN; Munoz-Sanjuan I; Yang XW
Sci Transl Med; 2014 Dec; 6(268):268ra178. PubMed ID: 25540325
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Biochemical Assay Analysis of Mutant Huntingtin Exon 1 Protein in R6/2 Mice.
Morozko EL; Ochaba J; Hernandez SJ; Lau A; Sanchez I; Orellana I; Kopan L; Crapser J; Duong JH; Overman J; Yeung S; Steffan JS; Reidling J; Thompson LM
J Huntingtons Dis; 2018; 7(4):321-335. PubMed ID: 30452420
[TBL] [Abstract][Full Text] [Related]
16. Early autophagic response in a novel knock-in model of Huntington disease.
Heng MY; Duong DK; Albin RL; Tallaksen-Greene SJ; Hunter JM; Lesort MJ; Osmand A; Paulson HL; Detloff PJ
Hum Mol Genet; 2010 Oct; 19(19):3702-20. PubMed ID: 20616151
[TBL] [Abstract][Full Text] [Related]
17. Time-resolved FRET screening identifies small molecular modifiers of mutant Huntingtin conformational inflexibility in patient-derived cells.
Wilbertz JH; Frappier J; Muller S; Gratzer S; Englaro W; Stanek LM; Calamini B
SLAS Discov; 2022 Jun; 27(4):219-228. PubMed ID: 35058188
[TBL] [Abstract][Full Text] [Related]
18. Small, Seeding-Competent Huntingtin Fibrils Are Prominent Aggregate Species in Brains of zQ175 Huntington's Disease Knock-in Mice.
Schindler F; Praedel N; Neuendorf N; Kunz S; Schnoegl S; Mason MA; Taxy BA; Bates GP; Khoshnan A; Priller J; Grimm J; Maier M; Boeddrich A; Wanker EE
Front Neurosci; 2021; 15():682172. PubMed ID: 34239412
[TBL] [Abstract][Full Text] [Related]
19. Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions.
Davranche A; Aviolat H; Zeder-Lutz G; Busso D; Altschuh D; Trottier Y; Klein FA
Hum Mol Genet; 2011 Jul; 20(14):2795-806. PubMed ID: 21518730
[TBL] [Abstract][Full Text] [Related]
20. mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntington's Disease.
Ast A; Buntru A; Schindler F; Hasenkopf R; Schulz A; Brusendorf L; Klockmeier K; Grelle G; McMahon B; Niederlechner H; Jansen I; Diez L; Edel J; Boeddrich A; Franklin SA; Baldo B; Schnoegl S; Kunz S; Purfürst B; Gaertner A; Kampinga HH; Morton AJ; Petersén Å; Kirstein J; Bates GP; Wanker EE
Mol Cell; 2018 Sep; 71(5):675-688.e6. PubMed ID: 30193095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
